Skip to main
MGTX

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings is a promising gene therapy company with a vertically integrated pipeline that includes targeted therapies for serious diseases such as Parkinson's and rare inherited retinal dystrophies. The recent partnership deal with Hologen for their Parkinson's program brings in much needed financing and support, and the company's strong manufacturing capabilities set them up for success in developing and commercializing their therapies. With multiple potential launches in the pipeline and a solid balance sheet, this company has the potential to become a commercial-stage success in the near future.

Bears say

MeiraGTx Holdings is a company with a promising pipeline but faces significant risks and uncertainties in terms of clinical program execution and regulatory approvals. Its success will depend on its ability to effectively demonstrate the efficacy of its treatments and maintain a competitive edge in the market. However, the company's focus on sustainable and disease-modifying options in areas with high unmet need could provide growth potential and increased value in the long term, if successful.

MGTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, MGTX has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.